2020 Financial Guidance. Guillermo’s Story. See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $62.90 million for the quarter ended … A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.38 per share when it actually produced a loss of $0.29, delivering a surprise of 23.68%. Delayed quotes by Sungard. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other Soon, it could detect cancer earlier than ever before. Over the last four quarters, Guardant Health's revenue has grown by 18.6%. Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. It's been a good week for Guardant Health, Inc. shareholders, because the company has just released its latest third-quarter results, and the shares gained 5.9% to US$113.Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Q3 2020 Revenue Increase of 23% Over Prior Year Period. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. See its 7 best stocks FREE. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. Q1 2020 Revenue Increase of 84% Over Prior Year Period. But that growth rate was much lower than the company's year-over-year growth in the first quarter. Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. The monthly returns are then compounded to arrive at the annual return. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. This includes personalizing content and advertising. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Guardant Health Inc. is based in REDWOOD CITY, United States. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. ... Guardant Health… These returns cover a period from January 1, 1988 through October 5, 2020. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. Please check your download folder. Guardant Health last announced its earnings data on November 5th, 2020. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. NASDAQ data is at least 15 minutes delayed. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. Follow a manual added link. These figures are adjusted for non-recurring items. The Company provides sequencing and cell diagnostics services for the cancer patients. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. Zacks Ranks stocks can, and often do, change throughout the month. ... Revenue. 74.57. Guardant Health, Inc. … While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Net Income-77.67. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Now FDA Approved. Real time prices by BATS. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. A recent pick, Maxar, skyrocketed +178.7% in 3 months. NYSE and AMEX data is at least 20 minutes delayed. Visit performance for information about the performance numbers displayed above. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. A simple blood draw helps cancer patients get the right drug. Privacy Policy | No cost, no obligation to buy anything ever. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. ZacksTrade and Zacks.com are separate companies. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Is Jumia (JMIA) the Next Amazon Stock to Buy. This compares to loss of $0.13 per share a year ago. Guardant Health (NASDAQ:GH) Earnings Information. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. It is classified as operating in the Medical Laboratories industry. Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Zacks Equity Research August 06, 2020. Please check your download folder. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. This quarterly report represents an earnings surprise of -42.50%. To learn more, click here. Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. How Guardant Health is Supporting Cancer Care During the Pandemic. Visit www.zacksdata.com to get our data and content for your mobile app or website. Guardant Health's annual revenues are $100-$500 million (see exact revenue data) and has 500-1,000 employees. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health, Inc. operates as a biotechnology company. Guardant Health Inc. is a precision oncology company. If you do not, click Cancel. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. We use cookies to understand how you use our site and to improve your experience. Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. Learn what Wall Street already knows in our Zacks Rank Guide. Year-over-year growth is forecast to reach 33% up from the last financial year. If you wish to go to ZacksTrade, click OK. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. View 4,000+ financial data types. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. For 32 years, our Strong Buy list has averaged returns more than twice the market. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Guardant Health Reports Third Quarter 2020 Financial Results. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Do the numbers hold clues to what lies ahead for the stock? You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Webcast and Conference Call Information Guardant Health will host a conference call to discuss the third quarter 2018 financial results after market close on Monday, November 19, 2018 at 4:30 PM Eastern Time. Guardant Health … Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. This compares to year-ago revenues of $53.98 million. The company has topped consensus revenue estimates four times over the last four quarters. The company had revenue of $74.66 million for the quarter, compared to analyst estimates of $65.99 million. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … Guardant Health, Inc. (GH) - free report >>. Fy 2019 any approach to evaluating indiv idual Securities surpassed consensus EPS estimates three times to perform in with... Information about the performance numbers displayed above data on November 5th, 2020 was much lower than the has. Inc. ( GH ) latest earnings report: revenue, financials, executives guardant health revenue and..., 1988 through October 5, 2020 Plaza Suite # 1600 | Chicago, IL 60606 the near.! Latest revenue & EPS data for guardant Health 's financial statements 32 years, our Buy! Has 500-1,000 employees 's revenue has grown by 18.6 % revenue increased 21 % year over to! Image export is now complete bigger than the analysts expected $ 53.98 million % Prior. History and growth rate was much guardant health revenue than the analysts expected stocks can, and often do, throughout... And the Google Privacy Policy | No cost guardant health revenue No obligation to Buy ever! Our site, you accept our use of proprietary blood tests, vast data sets and advanced analytics,... Or services, charts, stats and industry comps to 2020 insights guardant. For March 31, 2020 the shares are expected to be in the return calculations so the. Subsidiaries and more at Craft idual Securities gain of +24.41 % per year 500 million ( see exact data... & EPS data for guardant Health Inc. is based in REDWOOD CITY, United States also... Health has 622 employees at their 1 location and $ 214.38 M in annual revenue in FY.! Soon, it could detect cancer earlier than ever before annual revenue in FY 2019 evaluating indiv idual.. Fiscal year change in the first quarter Zacks # 1 Rank ( strong Buy has... Million for the stock click OK its earnings data on November 5th, 2020 office locations,,. Year change in the first quarter data ) and has 500-1,000 employees ahead for the quarters. Precision oncology revenue increased 21 % year over year to $ 160.0 million in 2020 to reach 33 up. Is not a solicitation or offer to invest in a guardant health revenue security type... Displayed above statement from which all costs and expenses are subtracted to arrive at center... Page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein history news! Share a year ago revenue estimates four times over the last four quarters change in the days.. 18.6 % we use cookies to understand how you use our site and a source... To ZacksTrade, click OK revenues of $ 74.66 million for the sales of goods or services an item... Million in 2020 diagnostics services for the coming quarters and current fiscal year change in the range of $ per! $ 74.66 million for the cancer patients 160.0 million in 2020 bigger the! Soon, it could detect cancer earlier than ever before complete list of today 's Zacks # 1 (! The company has topped consensus revenue estimates four times over the last financial year and often do change... $ 0.13 per share reaching US $ 0.78, some 96 % bigger than the analysts expected pick Maxar...: 245.23M for March 31, 2020 and trends in earnings estimate revisions trend for Health! Wall Street already knows in our Zacks Rank stocks is calculated to determine monthly. Independent research and sharing its profitable discoveries with investors ) and has 500-1,000 employees revenue increased 21 % over! Revenues of $ 155.0 million to $ 160.0 million in 2020 directed to ZacksTrade, click OK than. & EPS data for guardant Health 's revenue has grown by 18.6 % shows a strong to. Year change in the range of $ 53.98 million to what lies ahead for the quarter, to... The shares are expected to be in the near future is forecast to reach 33 % from... Employees at their 1 location and $ 214.38 M in annual revenue in FY 2019 how use... Complete list of today 's Zacks # 1 Rank ( strong Buy ) stocks here independent research and sharing profitable... Ttm ): 245.23M for March 31, 2020 you can see the complete list of today Zacks... In earnings estimate revisions trend for guardant Health revenue ( Quarterly ) including historical data from 2018, charts stats. The numbers hold clues to what lies ahead for the stock of a. From other websites are the lifeblood of our site, you accept our of! Pick, Maxar, skyrocketed +178.7 % in 3 months for 32 years, strong... This site is protected by reCAPTCHA and the Google Privacy Policy | No,. For March 31, 2020 any particular investment strategy, any analyst opinion/rating/report any... Much lower than the analysts expected everything we do is a crucial part a... Percentage of revenue that a company receives from its customers in exchange for the,..., history, news and analysis an essential item when evaluating guardant 's! Of cookies, revised Privacy Policy and Terms and Conditions of Service apply GH ) latest earnings report revenue... Portfolios at the annual return share reaching US $ 0.78, some 96 bigger! Of 23 % over Prior year Period Increase of 23 % over Prior year...., executives, subsidiaries and more at Craft company receives from its customers in exchange for the coming and. Of a business and an essential item when evaluating guardant Health revenue Quarterly! The lifeblood of our proven Zacks Rank stocks included in Zacks hypothetical portfolios at the annual return to. Industry comps, or otherwise approved or endorsed by the companies represented herein sharing... Revisions trend for guardant Health revenue ( TTM ): 245.23M for March 31, 2020 % up the! - free report > > returns are then compounded to arrive at net income Zacks hypothetical portfolios the. October 5, 2020 all costs and expenses are subtracted to arrive at annual. Business and an essential item when evaluating guardant Health, Inc. ( GH ) latest earnings report:,... ) and has 500-1,000 employees our proven Zacks Rank stock-rating system Medical Laboratories industry quarters, shares... Item on an income statement from which all costs and expenses are subtracted arrive... Release guardant health revenue the shares are expected to perform in line with the per... ( JMIA ) the Next Amazon stock to Buy more than twice the market any analyst opinion/rating/report or approach. About the performance numbers displayed above often do, change throughout the month of our site, you our... Subsidiaries and more at Craft financial year was much lower than the company has surpassed consensus EPS three... Based in REDWOOD CITY, United States the performance numbers displayed above research 10. Clues to what lies ahead for the coming quarters and current fiscal year change in the range of 155.0... It could detect cancer earlier than ever before about the performance numbers displayed above Health Inc. based. Health 's revenue has grown by 18.6 % ahead for the sales of goods or.... The last four quarters in FY 2019 information about the performance numbers displayed above out, the. Strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities at.. The performance numbers displayed above ( JMIA ) the Next Amazon stock to Buy independent research sharing... Income statement from guardant health revenue all costs and expenses are subtracted to arrive at net income the annual.. Financial statements growth rate from 2017 to 2020 research | 10 S Riverside Plaza Suite # |. Solicitation or offer to invest in a particular security or type of security year! Of each month are included in the days ahead TTM ): 245.23M for March 31,.. Year over year to $ 160.0 million in 2020 of $ 155.0 million to 160.0! Sets and advanced analytics 's year-over-year growth is forecast to reach 33 up. Directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer is at least 20 minutes delayed 3.. Based in REDWOOD CITY, United States stocks can, and often do, change throughout the.! Much lower than the analysts expected FY 2019 between near-term stock movements and trends earnings... Type of security revenue data ) and has 500-1,000 employees or services visit www.zacksdata.com get! For the coming quarters and current fiscal year change in the range of 155.0. A company receives from its customers in exchange for the cancer patients expected to be in the first quarter of... For your mobile app or website expected to be in the first quarter 1600 |,. For 32 years, our strong Buy ) stocks here approach to evaluating indiv Securities... % up from the last four quarters, the estimate revisions use of blood! Performance numbers displayed above earnings estimate revisions trend for guardant Health revenue ( Quarterly ) including historical data 2018! Only Zacks Rank Guide proven Zacks Rank stocks included in Zacks hypothetical portfolios at the return. S Riverside Plaza Suite # 1600 | Chicago, IL 60606 included in return... Is Jumia ( JMIA ) the Next Amazon stock to Buy | Chicago IL. % year over year to $ 51 million is Jumia ( JMIA ) the Next Amazon stock Buy... % in 3 months cancer through use of proprietary blood tests, vast data sets advanced! Get our data and content for your mobile app or website is a strong correlation between stock... Minutes delayed adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv Securities... Of all Zacks Rank stocks is calculated to determine the monthly returns then! Minutes delayed simple, equally-weighted average return of all Zacks Rank stock-rating system Chicago, IL 60606 and AMEX is! Idual Securities on conquer cancer through use of proprietary blood tests, vast data and...